Perfectus Biomed Limited, are excited to officially announce that our merger with Wyoming based laboratory, Extherid Biosciences, has now been completed. The merger brings together a breadth of industry experience and expands our service offering and geographical reach. The merger is a positive step for our clients as it will result in an expanded and integrated in vitro and ex vivo service offering.

Prior to the merger both companies focused on customised testing that supported their client’s product development and regulatory journeys.  Clients with multinational needs requiring such support will continue to receive the quality they have come to know and expect from Perfectus Biomed but with added expertise in both geographies, increasing testing capabilities.

Perfectus Biomed is ISO 9001 certified. In the U.K. division, services are UKAS accredited and GLP compliant. Specialist services include accredited biofilm testing, microbiology, molecular biology, cell culture and virology and these services are offered to medical devices, wound care, pharmaceutical, cosmetic and biocidal sectors.

The U.S. facility’s expertise lies in experimental therapeutics and preclinical infectious disease research through customisable tissue models.  The facility provides specialist research for the medical device, urogenital health, wound care, inflammation and biocompatibility sectors.

The merger will drive continued growth plans over the coming months and years with development opportunities arising for existing staff as well as creating recruitment opportunities from across our target segments.

Effective June 2020:

Perfectus Biomed Ltd will continue to be known as Perfectus Biomed Ltd.

Extherid Biosciences will be known as Perfectus Biomed LLC.

To keep up to date with Perfectus Biomed Group’s international developments please follow us on LinkedIn and Twitter, and reach out to our teams via info@perfectusbiomed.com.

COVID-19
Get in Touch